Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 14(7): e0219592, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31356639

RESUMO

Chromosome abnormalities induces profound alterations in gene expression, leading to various disease phenotypes. Recent studies on yeast and mammalian cells have demonstrated that aneuploidy exerts detrimental effects on organismal growth and development, regardless of the karyotype, suggesting that aneuploidy-associated stress plays an important role in disease pathogenesis. However, whether and how this effect alters cellular homeostasis and long-term features of human disease are not fully understood. Here, we aimed to investigate cellular stress responses in human trisomy syndromes, using fibroblasts and induced pluripotent stem cells (iPSCs). Dermal fibroblasts derived from patients with trisomy 21, 18 and 13 showed a severe impairment of cell proliferation and enhanced premature senescence. These phenomena were accompanied by perturbation of protein homeostasis, leading to the accumulation of protein aggregates. We found that treatment with sodium 4-phenylbutyrate (4-PBA), a chemical chaperone, decreased the protein aggregates in trisomy fibroblasts. Notably, 4-PBA treatment successfully prevented the progression of premature senescence in secondary fibroblasts derived from trisomy 21 iPSCs. Our study reveals aneuploidy-associated stress as a potential therapeutic target for human trisomies, including Down syndrome.


Assuntos
Senescência Celular , Fibroblastos/patologia , Agregados Proteicos , Trissomia/patologia , Aneuploidia , Proliferação de Células/efeitos dos fármacos , Senescência Celular/efeitos dos fármacos , Metabolismo Energético/efeitos dos fármacos , Fibroblastos/efeitos dos fármacos , Fibroblastos/metabolismo , Glucose/metabolismo , Humanos , Células-Tronco Pluripotentes Induzidas/efeitos dos fármacos , Células-Tronco Pluripotentes Induzidas/metabolismo , Lactatos/metabolismo , Mitocôndrias/efeitos dos fármacos , Mitocôndrias/patologia , Estresse Oxidativo/efeitos dos fármacos , Fenilbutiratos/farmacologia , Agregados Proteicos/efeitos dos fármacos , RNA/metabolismo , Trissomia/genética
2.
Sci Rep ; 7(1): 764, 2017 04 10.
Artigo em Inglês | MEDLINE | ID: mdl-28396582

RESUMO

Eukaryotic genomes are organised into complex higher-order structures within the nucleus, and the three-dimensional arrangement of chromosomes is functionally important for global gene regulation. The existence of supernumerary chromosome 21 in Down syndrome may perturb the nuclear architecture at different levels, which is normally optimised to maintain the physiological balance of gene expression. However, it has not been clearly elucidated whether and how aberrant configuration of chromosomes affects gene activities. To investigate the effects of trisomy 21 on nuclear organisation and gene expression, we performed three-dimensional fluorescent imaging analysis of chromosome-edited human induced pluripotent stem cells (iPSCs), which enabled identification of the parental origin of the three copies of chromosome 21. We found that two copies of maternal chromosomes resulting from meiotic nondisjunction had a higher tendency to form an adjacent pair and were located relatively distant from the nuclear membrane, suggesting the conserved interaction between these homologous chromosomes. Transcriptional profiling of parental-origin-specific corrected disomy 21 iPSC lines indicated upregulated expression of the maternal alleles for a group of genes, which was accompanied by a fluctuating expression pattern. These results suggest the unique effects of a pair of maternal chromosomes in trisomy 21, which may contribute to the pathological phenotype.


Assuntos
Cromossomos Humanos Par 21 , Síndrome de Down/diagnóstico , Síndrome de Down/genética , Herança Materna , Meiose , Não Disjunção Genética , Transcrição Gênica , Linhagem Celular , Núcleo Celular/genética , Regulação da Expressão Gênica , Marcação de Genes , Loci Gênicos , Humanos , Hibridização in Situ Fluorescente , Células-Tronco Pluripotentes Induzidas/metabolismo , Fenótipo , Trissomia
3.
Cell Rep ; 15(6): 1228-41, 2016 05 10.
Artigo em Inglês | MEDLINE | ID: mdl-27134169

RESUMO

Chromosomal aneuploidy and specific gene mutations are recognized early hallmarks of many oncogenic processes. However, the net effect of these abnormalities has generally not been explored. We focused on transient myeloproliferative disorder (TMD) in Down syndrome, which is characteristically associated with somatic mutations in GATA1. To better understand functional interplay between trisomy 21 and GATA1 mutations in hematopoiesis, we constructed cellular disease models using human induced pluripotent stem cells (iPSCs) and genome-editing technologies. Comparative analysis of these engineered iPSCs demonstrated that trisomy 21 perturbed hematopoietic development through the enhanced production of early hematopoietic progenitors and the upregulation of mutated GATA1, resulting in the accelerated production of aberrantly differentiated cells. These effects were mediated by dosage alterations of RUNX1, ETS2, and ERG, which are located in a critical 4-Mb region of chromosome 21. Our study provides insight into the genetic synergy that contributes to multi-step leukemogenesis.


Assuntos
Cromossomos Humanos Par 21/genética , Síndrome de Down/genética , Epistasia Genética , Fator de Transcrição GATA1/genética , Hematopoese/genética , Modelos Biológicos , Mutação/genética , Pareamento de Bases/genética , Sequência de Bases , Diferenciação Celular/genética , Linhagem da Célula/genética , Eritropoese/genética , Técnicas de Inativação de Genes , Humanos , Células-Tronco Pluripotentes Induzidas/metabolismo , Megacariócitos/patologia , Edição de RNA/genética , Deleção de Sequência , Fatores de Transcrição/metabolismo , Regulação para Cima/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA